Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Sepracor Announces 940 Layoffs; Achieves the Impossible on Lunesta Sales
- Back in August, BNET ragged on Sepracor for implementing a cost-cutting program that drove up its expenses and drove down its revenue. In its Q4 earnings today, the company has turned that all around -- sales are up and expenses are down. The turnaround has come at...
- Blog posts 2009-01-29
Additional Resources
- End of Sepracor-GSK Deal Raises Question in Lunesta Patent Fight
- Here's something that few noticed in Sepracor's Q1 2009 earnings announcement: The company's $155 million marketing deal for insomnia drug Lunesta/Lunivia with GlaxoSmithKline in Europe fell through. The collapse of the deal was predictable. I noted in July 2008 that GSK's subsequent $3.3 billion deal with Actelion...
- Blog posts 2009-06-13
- Insomnia and Antidepressant Sales Give Lie to DTC Myths
- Direct-to-consumer drug advertising has almost no relationship with consumer demand for prescriptions. That is one interpretation of a story in Ad Age showing that scrips for insomnia pills (such as Sanofi-Aventis's Ambien CR) and antidepressants (such as Eli Lilly's Cymbalta) are up, even though advertising in both those categories is...
- Blog posts 2009-03-05
- Sepracor Has Stopped Advertising Lunesta, But Sales Still Go Up
- Sepracor appears to have almost stopped advertising for sleeping pill Lunesta, and yet sales are still rising. Sepracor spent less than $1 million on ads for the brand in 2009, but Lunesta sales were up 2 percent to $151 million in Q2 2009. by Jim Edwards
- Blog posts 2009-09-15
- Top Lunesta marketer leaves Sepracor
- TIM HEALEY, the marketer who helped Sepracor reap first-year Lunesta sales of $465 million with an unparalleled DTC campaign, has jumped ship and joined a small nanoparticle company.
- Research articles 2007-01-01
- Isiah Thomas Overdose Indicates Lunesta Has Chink in Armor
- Until now, Sepracor’s Lunesta sleeping pill has enjoyed one advantage over Sanofi-Aventis’s Ambien CR: a superior reputation for safety. The drug is approved by the FDA for long-term use, unlike many of its rivals. And it’s not a benzodiazepine. That reputation changed over the weekend as it...
- Blog posts 2008-10-26
- Sepracor Q2: More Miracles From Marlborough
- Sepracor has once again achieved the impossible by growing sales of its sleeping pill Lunesta despite an almost infinite number of generic and OTC competitors. Lunesta sales were up 2 percent to $151 million in Q2 2009, the company reported. by Jim Edwards
- Blog posts 2009-07-24
- Sepracor boosts rep ranks for Lunesta
- SEPRACOR IS expanding its sales force by 50% in an attempt to hit 2 million details for its insomnia drug Lunesta eszopiclone, the company said.
- Research articles 2006-03-01
- Research and Markets: In 2005, Sepracor's New Insomnia Drug Lunesta Accounted for the Greatest Single Drug Investment in DTC Advertising with a Total US Spend of $227.3M
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c55281) has announced the addition of "Winning Product Launch Strategies: Maximizing sales from new pharmaceutical products" to their offering
- Research articles 2007-04-27
- Sepracor Inc. Q1 2009 Earnings Call Transcript
- Question-and-Answer Session Operator Thank you, Mr. Adams. The floor is now open for questions. Operator Instructions. And our first question is coming from the line of Manoj Garg with Soleil Securities. Please go ahead, your line is open. Manoj Garg - Soleil Group Hey, good morning guys. I’ve...
- Earnings calls 2009-05-04
- Sepracor Q3 2007 Earnings Call Transcript
- Question-and-Answer Session Operator Certainly. The floor is now open for questions. Operator Instructions. Our first question is coming from Greg Gilbert of Merrill Lynch. Please go ahead. Greg Gilbert - Merrill Lynch Thanks, good morning. I have a couple, first can you share what tax rate assumptions you are...
- Earnings calls 2007-10-30
- Sepracor Inc. Q1 2006 Earnings Conference Call Transcript (SEPR)
- Question-and-Answer SessionOperator Thank you. Operator instructions. Your first question is from Greg Gilbert of Merrill Lynch. Q – Greg Gilbert, Merrill Lynch Thanks, I have a couple. First for Jim O’Shea. Jim, you mentioned that the 9% price increase for LUNESTA was...
- Earnings calls 2006-04-25
- Sepracor Inc. Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you, and ladies and gentlemen, the floor is now open for questions. Operator instructions And the first question today will come from the line of Manoj Garg with Soleil Securities. And your line is open. Manoj Garg – Soleil Securities Hey. Good morning, guys. I have...
- Earnings calls 2009-02-11
- At Sepracor, a Cost-Cutting Exercise Proves Expensive
- Last year, Sepracor, the maker of sleeping pill Lunesta, announced it would reduce its sales and marketing expenses by $90-100 million in 2008, "including an anticipated reduction of approximately 300 sales force positions." The company said it needed to make the layoffs because, by last October, its revenues were falling....
- Blog posts 2008-08-13
- Sepracor Announces Second Quarter 2005 Operating Results
- MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the second quarter of 2005. For the three months ended June 30, 2005, Sepracor's consolidated revenues were $185.1 million, of which revenues from pharmaceutical product sales were $166.7 million ($83.2 million for sales of XOPENEXR brand...
- Research articles 2005-07-19
- Sepracor Announces Third Quarter 2005 Operating Results
- MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the third quarter of 2005. For the three months ended September 30, 2005, Sepracor's consolidated revenues were $205.7 million, of which revenues from pharmaceutical product sales were $193.4 million ($92.5 million for sales of XOPENEXR brand...
- Research articles 2005-10-25
- Sepracor Announces Third Quarter 2006 Operating Results
- MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the third quarter of 2006. For the three months ended September 30, 2006, Sepracor's consolidated revenues were $289.3 million, of which revenues from pharmaceutical product sales were $280.1 million ($138.5 million for sales of XOPENEX([R]) brand...
- Research articles 2006-10-26
- Sepracor Inc. Q2 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Ladies and gentlemen the floor is now opened for questions. Operator instructions Our first question comes from the line of Chris Schott with JP Morgan. Please go ahead. Chris Schott – JP Morgan Great. Thanks. Just a couple of quick questions. May be to start...
- Earnings calls 2009-07-24
- Sepracor Announces Second Quarter 2006 Operating Results
- MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the second quarter of 2006. For the three months ended June 30, 2006, Sepracor's consolidated revenues were $264.4 million, of which revenues from pharmaceutical product sales were $256.4 million (XOPENEXR brand levalbuterol franchise revenues were $117.3...
- Research articles 2006-07-21
- Insomnia Pill Makers Go After Elderly With New 'Fear of Falling'
- For years, drug companies have tried to expand the range of prescriptions of sleeping pills. They're not just for sleeping any more -- now they're also for avoiding "rebound insomnia" in the elderly, "increased risk of automotive crashes, decreased work performance ... or mood changes," generalized anxiety disorder, and depression....
- Blog posts 2008-09-11
- << Previous
- page 1 of 1
- Next >>
